Advertisement

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Amit Sanyal, MD: A Clinician’s Perspective

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Mar
05
Today In Oncology
Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes
CD123-Targeting ADC Shows Activity in AML and BPDCN
Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds
Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence
Research Suggests AI Pathology Models May Take Unreliable Shortcuts to Identify Cancer Biomarkers
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo